Profile
| Metric | Value |
|---|---|
| Full Name | Ionis Pharmaceuticals, Inc. |
| Ticker | NASDAQ: IONS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | ionis.com |
| Employees | 1,069 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $81.66 | |
| Price, 1D Change | +1.69% | |
| Market Cap | $13B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.73 | |
| Revenue | $705M | |
| Revenue, 1Y Change | -10.48% | |
| EPS | -$3.04 | |
| EPS, 1Y Change | -18.68% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | ISIS | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$3.04 | |
| EPS Estimate | -$1.69 | |
| EPS Est. Change | +44.23% | |
| Revenue | $705.14M | |
| Revenue Estimate | $895.85M | |
| Revenue Est. Change | +27.05% | |
| Current Price | $81.66 | |
| Price Target | - | $95.00 |
| Price Tgt. Change | - | +16.34% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$3.29 | -$2.56 | +22.25% | |
| -$2.54 | -$3.04 | -19.31% | |
| -$1.69 | N/A | +44.23% | |
| -$2.32 | N/A | +23.71% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $635.98M | $787.65M | +23.85% | |
| $620.13M | $705.14M | +13.71% | |
| $895.85M | N/A | +27.05% | |
| $909.70M | N/A | +29.01% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +144.05% | |
| Price, 3Y | +109.22% | |
| Market Cap, 1Y | +150.34% | |
| Market Cap, 3Y | +138.56% | |
| Revenue, 1Y | -10.48% | |
| Revenue, 3Y | -12.99% | |
| EPS, 1Y | -18.68% | |
| EPS, 3Y | -1,396.94% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $81.66 | |
| SMA 200 | $52.91 | |
| SMA 200 vs Price | -35.21% | |
| SMA 50 | $77.72 | |
| SMA 50 vs Price | -4.82% | |
| Beta | 0.73 | |
| ATR | $2.63 | |
| 14-Day RSI | 52.67 | |
| 10-Day Volatility | 28.77% | |
| 1-Year Volatility | 52.47% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $705.14M | |
| EPS | -$3.04 | |
| Gross Profit | $671.93M | |
| Gross Margin | 95.29% | |
| Operating Profit | -$475.11M | |
| Operating Margin | -67.38% | |
| Net Income | -$453.90M | |
| Net Margin | -64.37% | |
| EBITDA | -$353.72M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 2.13 | |
| Current Ratio | 8.47 | |
| Quick Ratio | 8.43 | |
| - | ||
| F-Score | 4 | |
| Altman Z-Score | 2.98 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 13.67 | |
| PB Ratio | 21.40 | |
| EV/EBITDA | -50.79 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $588.35M | |
| Cash & Equivalents | $242.08M | |
| Total Assets | $3.00B | |
| Current Assets | $2.62B | |
| Total Liabilities | $2.42B | |
| Current Liabilities | $309.32M | |
| Total Debt | $1.96B | |
| Short Term Debt | $9.28M | |
| Accounts Payable | $42.96M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $1.18B | |
| Operating Expenses | $1.17B | |
| Cost Of Goods Sold | $33.21M | |
| SG&A | $267.50M | |
| D&A | $21.99M | |
| Interest Expense | $0.00 | |
| Income Tax | -$6.17M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$500.95M | |
| CFI | -$134.03M | |
| CFF | $478.06M | |
| Capex | $50.34M | |
| Free Cash Flow | -$551.29M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | → | |
| RBC Capital | → | |
| Leerink Partners | → | |
| B of A Securities | → | |
| HC Wainwright & Co. | → | |
| Piper Sandler | → | |
| TD Cowen | → | |
| Raymond James | → | |
| RBC Capital | → | |
| Needham | → |
Analyst sentiment
Institutional ownership
Screeners with IONS
Data Sources & References
- IONS Official Website www.ionis.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/874015/000087401525000089/0000874015-25-000089-index.htm
- IONS Profile on Yahoo Finance finance.yahoo.com/quote/IONS
- IONS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/ions
FAQ
What is the ticker symbol for Ionis Pharmaceuticals, Inc.?
The ticker symbol for Ionis Pharmaceuticals, Inc. is NASDAQ:IONS
Does Ionis Pharmaceuticals, Inc. pay dividends?
No, Ionis Pharmaceuticals, Inc. does not pay dividends
What sector is Ionis Pharmaceuticals, Inc. in?
Ionis Pharmaceuticals, Inc. is in the Healthcare sector
What industry is Ionis Pharmaceuticals, Inc. in?
Ionis Pharmaceuticals, Inc. is in the Biotechnology industry
What country is Ionis Pharmaceuticals, Inc. based in?
Ionis Pharmaceuticals, Inc. is headquartered in United States
When did Ionis Pharmaceuticals, Inc. go public?
Ionis Pharmaceuticals, Inc. initial public offering (IPO) was on May 17, 1991
Is Ionis Pharmaceuticals, Inc. in the S&P 500?
No, Ionis Pharmaceuticals, Inc. is not included in the S&P 500 index
Is Ionis Pharmaceuticals, Inc. in the NASDAQ 100?
No, Ionis Pharmaceuticals, Inc. is not included in the NASDAQ 100 index
Is Ionis Pharmaceuticals, Inc. in the Dow Jones?
No, Ionis Pharmaceuticals, Inc. is not included in the Dow Jones index
When was Ionis Pharmaceuticals, Inc. last earnings report?
Ionis Pharmaceuticals, Inc.'s most recent earnings report was on October 29, 2025
When does Ionis Pharmaceuticals, Inc. report earnings?
The next expected earnings date for Ionis Pharmaceuticals, Inc. is February 18, 2026